Cerebrospinal fluid amyloid β1-42 levels in the mild cognitive impairment stage of Alzheimer's disease

Masahiro Maruyama, Hiroyuki Arai, Mitsunori Sugita, Haruko Tanji, Makoto Higuchi, Nobuyuki Okamura, Toshifumi Matsui, Susumu Higuchi, Sachio Matsushita, Hiroshi Yoshida, Hidetada Sasaki

研究成果: Article査読

88 被引用数 (Scopus)


Cerebrospinal fluid (CSF) levels of amyloid β-protein ending at amino acid position 42 (CSF-A β1-42) and CSF-tau levels were quantified by sandwich ELISAs in 19 patients with mild cognitive impairment (MCI) who eventually developed Alzheimer's disease (AD) on follow-up as well as in 15 age-matched normal controls and 54 AD patients at diverse stages of the disease. In the present study, the annual conversion rate was approximately 15%. The CSF-A β1-42 levels did not differ significantly between the normal control group and the MCI group, however, these values declined significantly once AD became clinically overt. In contrast to CSF-A β1-42, CSF-tau levels were significantly increased in the MCI stage, and these values continued to be elevated thereafter, indicating that increased levels of CSF-tau may help in detecting MCI subjects who are predicted to develop AD. We propose that CSF-tau and CSF-A β1-42 must be used as two distinct biomarkers that should be applied appropriately in clinical settings.

ジャーナルExperimental Neurology
出版ステータスPublished - 2001

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

フィンガープリント 「Cerebrospinal fluid amyloid β<sub>1-42</sub> levels in the mild cognitive impairment stage of Alzheimer's disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。